Genentech, Inc. - Product Pipeline Review - 2016

  • ID: 3635609
  • Company Profile
  • 128 pages
  • Global Markets Direct
  • Genentech, Inc.
1 of 4
Genentech, Inc. - Product Pipeline Review - 2016

Summary

The report ‘Genentech, Inc. - Product Pipeline Review - 2016’, provides an overview of the Genentech, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genentech, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Genentech, Inc.
- The report provides overview of Genentech, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Genentech, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Genentech, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Genentech, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genentech, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genentech, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Genentech, Inc. Snapshot

Genentech, Inc. Overview

Key Information

Key Facts

Genentech, Inc. - Research and Development Overview

Key Therapeutic Areas

Genentech, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Genentech, Inc. - Pipeline Products Glance

Genentech, Inc. - Late Stage Pipeline Products

Genentech, Inc. - Clinical Stage Pipeline Products

Genentech, Inc. - Early Stage Pipeline Products

Genentech, Inc. - Drug Profiles

crenezumab

etrolizumab

lampalizumab

taselisib

duligotuzumab

ipatasertib

polatuzumab vedotin

quilizumab

RG-6046

RG-7745

BFKB-8488A

BTCT-4465A

DMUC-4064A

Drug for Inflammatory Diseases

DSTA-4637S

GDC-0134

GDC-0927

lifastuzumab vedotin

RG-6024

RG-6029

RG-7741

RG-7828

RG-7842

RG-7845

RG-7882

RG-7888

RG-7893

CS-3

G-007LK

G-244LM

GNE-293

GNE-317

GNE-3511

GNE-555

GNE-7915

GNE-892

MAb-30D8

Monoclonal Antibodies to Target CD98hc and BACE for Alzheimer's Disease

Monoclonal Antibody Conjugate for B-Cell Non Hodgkin's Lymphoma

Monoclonal Antibody Conjugates for Oncology

Monoclonal Antibody to Inhibit HtrA1 for Age Related Macular Degeneration

Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease and Neurodegenerative Disorders

MV-1

pictilisib

Small Molecule to Inhibit BACE1 for Alzheimer’s Disease

Small Molecule to Inhibit MAP4K4 for Cancer

Small Molecule to Inhibit TYK2 for Psoriasis and IBD

Small Molecules to Inhibit IRAK4 for Immunology and Oncology

Small Molecules to Inhibit JAK2 for Cancer

Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms

Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma

Small Molecules to Inhibit NAMPT for Cancer

Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders

Monoclonal Antibody Conjugated for Cancer

Small Molecule 2 for Undisclosed Indication

Small Molecule to Inhibit ITK for Asthma

Small Molecules 1 for Undisclosed Indication

Small Molecules for Central Nervous System Disorders

Small Molecules for Undisclosed Indication

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation

Small Molecules to Inhibit EGFR for Non-Small Cell Lung Cancer

Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases

Small Molecules to Inhibit Ubiquitin Specific Protease for Oncology

Genentech, Inc. - Pipeline Analysis

Genentech, Inc. - Pipeline Products by Target

Genentech, Inc. - Pipeline Products by Route of Administration

Genentech, Inc. - Pipeline Products by Molecule Type

Genentech, Inc. - Pipeline Products by Mechanism of Action

Genentech, Inc. - Recent Pipeline Updates

Genentech, Inc. - Dormant Projects

Genentech, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Genentech, Inc. - Company Statement

Genentech, Inc. - Locations and Subsidiaries

Head Office

Other Locations & Subsidiaries

Genentech, Inc. - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Genentech, Inc., Key Information

Genentech, Inc., Key Facts

Genentech, Inc. - Pipeline by Indication, 2016

Genentech, Inc. - Pipeline by Stage of Development, 2016

Genentech, Inc. - Monotherapy Products in Pipeline, 2016

Genentech, Inc. - Partnered Products in Pipeline, 2016

Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Genentech, Inc. - Out-Licensed Products in Pipeline, 2016

Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Genentech, Inc. - Phase III, 2016

Genentech, Inc. - Phase II, 2016

Genentech, Inc. - Phase I, 2016

Genentech, Inc. - Preclinical, 2016

Genentech, Inc. - Discovery, 2016

Genentech, Inc. - Pipeline by Target, 2016

Genentech, Inc. - Pipeline by Route of Administration, 2016

Genentech, Inc. - Pipeline by Molecule Type, 2016

Genentech, Inc. - Pipeline Products by Mechanism of Action, 2016

Genentech, Inc. - Recent Pipeline Updates, 2016

Genentech, Inc. - Dormant Developmental Projects,2016

Genentech, Inc. - Discontinued Pipeline Products, 2016

Genentech, Inc., Other Locations

Genentech, Inc., Key Manufacturing Facilities

List of Figures

Genentech, Inc. - Pipeline by Top 10 Indication, 2016

Genentech, Inc. - Pipeline by Stage of Development, 2016

Genentech, Inc. - Monotherapy Products in Pipeline, 2016

Genentech, Inc. - Partnered Products in Pipeline, 2016

Genentech, Inc. - Out-Licensed Products in Pipeline, 2016

Genentech, Inc. - Pipeline by Top 10 Target, 2016

Genentech, Inc. - Pipeline by Route of Administration, 2016

Genentech, Inc. - Pipeline by Molecule Type, 2016

Genentech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll